a small-molecule inhibitor
ChemicalBook > CAS DataBase List > Imatinib mesylate

Imatinib mesylate

a small-molecule inhibitor
Product Name
Imatinib mesylate
CAS No.
220127-57-1
Chemical Name
Imatinib mesylate
Synonyms
GLEEVEC;GLIVEC;Imatinib (Glivec);STI-571;Gleevac;CGP 57148;CGP54148B;Genfatinib;CGP-57148B;tinib Mesylate
CBNumber
CB7173646
Molecular Formula
C30H35N7O4S
Formula Weight
589.71
MOL File
220127-57-1.mol
More
Less

Imatinib mesylate Property

Melting point:
214-224°C
storage temp. 
2-8°C
solubility 
H2O: soluble10mg/mL, clear
form 
White solid
color 
white to beige
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20°C for up to 3 months.
InChI
InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
InChIKey
YLMAHDNUQAMNNX-UHFFFAOYSA-N
SMILES
C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)(=O)C1=CC=C(CN2CCN(C)CC2)C=C1.CS(O)(=O)=O
CAS DataBase Reference
220127-57-1(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn
Risk Statements 
22
WGK Germany 
3
RTECS 
CV5520550
HS Code 
29350090
Hazardous Substances Data
220127-57-1(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML1027
Product name
Imatinib mesylate
Purity
≥98% (HPLC)
Packaging
10mg
Price
$43.5
Updated
2024/03/01
Sigma-Aldrich
Product number
SML1027
Product name
Imatinib mesylate
Purity
≥98% (HPLC)
Packaging
100mg
Price
$149
Updated
2024/03/01
Sigma-Aldrich
Product number
5.04595
Product name
Bcr-abl Inhibitor IV, Imatinib - CAS 220127-57-1 - Calbiochem
Packaging
50mg
Price
$155
Updated
2024/03/01
TCI Chemical
Product number
I0936
Product name
Imatinib Mesylate
Purity
>98.0%(HPLC)
Packaging
100mg
Price
$54
Updated
2024/03/01
TCI Chemical
Product number
I0936
Product name
Imatinib Mesylate
Purity
>98.0%(HPLC)
Packaging
1g
Price
$314
Updated
2024/03/01
More
Less

Imatinib mesylate Chemical Properties,Usage,Production

a small-molecule inhibitor

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Description

In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. This compound can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloride of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.

Chemical Properties

Off-White Solid

Originator

Novartis (Switzerland)

Uses

A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)

Uses

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib

Uses

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

Uses

echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis

Definition

ChEBI: A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.

brand name

Gleevec, Glivec

General Description

Imatinib is available in 100- and 400-mg capsules for oraladministration and is indicated for the treatment of CML,gastrointestinal stromal tumors (GIST) that express Kit andacute lymphoplastic leukemia that is positive for thePhiladelphia chromosome.
Bioavailability of the agent is nearly 100% by the oralroute. The agent is highly protein bound and metabolized tothe N-desmethyl derivative by CYP3A4-mediated removalof the piperazinyl methyl group. The resulting metabolite issimilar to the parent in activity. Elimination occurs primarilyin the feces, and the terminal half-life is 18 hours forthe parent and 40 hours of the N-desmethyl metabolite.Resistant forms of the TK are known, which have alteredamino acids that prevent binding. In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. Severe side effects include ascites,neutropenia, thrombocytopenia, skin rash, andpulmonary edema. Less serious side effects include nausea/vomiting, heartburn, and headache but overall, the agentis better tolerated than most other medications used in treatingthe disease.

Biochem/physiol Actions

Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. Imatinib is a potent inhibitor of the Bcr-Abl kinase encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Imatinib mesylate inhibition of Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML decreases proliferation and enhances apoptosis in leukemias CML and ALL. Inhibition of c-kit tyrosine activity inhibits mast-cell and cellular proliferation in those diseases overexpressing c-kit such as gastrointestinal stromal tumor (GIST).

storage

+4°C

References

1) Buchdunger, et al.(1996) Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylpyrimidine Derivative; Cancer Res. 56 100 2) Heinrich et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 925 3) Morioka et al. (2016) Effect of Collagen Type 1 or Human Fibronectin on Imatinib Cytotoxicity in Oral Squamous Cell Carcinoma; Pharmacology and Pharmacy, 7 255 [Focus Biomolecules Citation] 4) Hazekawa et al. (2017) Assessment of cytotoxicity of imatinib for oral squamous cell carcinoma by a real-time cell analysis system; E. J. Bio., 13 56 [ Focus Biomolecules Citation]

Imatinib mesylate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Imatinib mesylate Suppliers

Americas 1 Argentina 1 Australia 1 Brazil 2 Canada 8 China 525 China Hong Kong 1 Cyprus 1 Czech Republic 2 Europe 4 France 2 Germany 6 Greece 1 India 114 Israel 1 Italy 1 Japan 1 Jordan 1 Latvia 1 Mexico 1 Poland 2 South Korea 5 Spain 1 Switzerland 2 The Netherlands 1 Turkey 1 United Arab Emirates 1 United Kingdom 14 United States 66 Global 768
Pure Chemistry Scientific Inc.
Tel
001-857-928-2050 or 1-888-588-9418
Fax
001-617-206-9595
Email
sales@chemreagents.com
Country
United States
ProdList
10186
Advantage
62
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
Alfa Chemistry
Tel
Fax
1-516-927-0118
Email
Info@alfa-chemistry.com
Country
United States
ProdList
24072
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
Focus Biomolecules
Tel
--
Fax
--
Email
sales@focusbiomolecules.com
Country
United States
ProdList
1284
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
Alan Scientific Inc.
Tel
--
Fax
--
Email
sales@alanscientific.com
Country
United States
ProdList
51
Advantage
58
Exim-Indis, Inc. (part of Exim Corporation and Indis N.V.)
Tel
--
Fax
--
Email
info@exim-indis.com
Country
United States
ProdList
440
Advantage
58
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
CQ INTERNATIONAL CO INC
Tel
--
Fax
--
Email
info@cqici.com
Country
United States
ProdList
76
Advantage
58
SHAMROCK INDUSTRIAL CO. LTD.
Tel
--
Fax
--
Email
pharma@shamrockindia.com
Country
United States
ProdList
119
Advantage
43
Aris Pharmaceutical, Inc.
Tel
--
Fax
--
Email
sales@arispharma.com
Country
United States
ProdList
27
Advantage
0
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
Genegobio Inc.
Tel
--
Fax
--
Email
mark@genegobio.com
Country
United States
ProdList
195
Advantage
0
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
SST Corporation
Tel
--
Fax
--
Email
info@sst-corp.com
Country
United States
ProdList
237
Advantage
38
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Axon Medchem LLC
Tel
--
Fax
--
Email
info@axonmedchem.com
Country
United States
ProdList
763
Advantage
58
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
TCI America
Tel
--
Fax
--
Email
sales@tciamerica.com
Country
United States
ProdList
6909
Advantage
75
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Anisyn, Inc.
Tel
--
Fax
--
Email
sales@anisyn.com
Country
United States
ProdList
863
Advantage
0
Ivy Fine Chemicals
Tel
--
Fax
--
Email
sales@ivychem.com
Country
United States
ProdList
6493
Advantage
58
Molcan Corporation
Tel
--
Fax
--
Email
info@molcan.com
Country
United States
ProdList
686
Advantage
60
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
Acanthus Research
Tel
--
Fax
--
Email
inquiries@acanthusresearch.com
Country
United States
ProdList
46
Advantage
50
Olinax Inc.
Tel
--
Fax
--
Email
info@olinax.com
Country
United States
ProdList
404
Advantage
50
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
W & J PharmaChem, Inc.
Tel
--
Fax
--
Email
info@wjpharmachem.com
Country
United States
ProdList
595
Advantage
50
Tecoland Corporation
Tel
--
Fax
--
Email
info@tecoland.com
Country
United States
ProdList
275
Advantage
50
Tinib-Tools
Tel
--
Fax
--
Country
United States
ProdList
164
Advantage
0
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Exlcusive Chemistry Ltd
Tel
--
Fax
--
Country
United States
ProdList
446
Advantage
71
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
HBCChem Inc.
Tel
--
Fax
--
Email
sales@hbcchem-inc.com
Country
United States
ProdList
4569
Advantage
30
Rintech, Inc.
Tel
--
Fax
--
Email
info@rintechinc.com
Country
United States
ProdList
3416
Advantage
60
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6962
Advantage
56
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
More
Less

View Lastest Price from Imatinib mesylate manufacturers

Sinoway Industrial co., ltd.
Product
Imatinib Mesylate 220127-57-1
Price
US $650.00-350.00/KG
Min. Order
1KG
Purity
High Density
Supply Ability
20 tons
Release date
2023-11-03
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Imatinib mesylate 220127-57-1
Price
US $0.00-0.00/Kg/Drum
Min. Order
1KG
Purity
98%-102% HPLC
Supply Ability
500KGS
Release date
2021-07-05
Nanjing Fred Technology Co., Ltd
Product
Imatinib mesylate 220127-57-1
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99.9%(HPLC)
Supply Ability
10 tons
Release date
2023-12-06

220127-57-1, Imatinib mesylateRelated Search:

2-Aminopyridine Methyl acrylate Thiophanate-methyl 3-Aminopyridine Gatifloxacin mesylate Pazufloxacin mesilate Pefloxacin mesylate Methyl acetate Methylparaben Bensulfuron methyl 4-Dimethylaminopyridine Kresoxim-methyl Methyl 1,2,3-Triacetyl-5-deoxy-D-ribose Gemcitabine Gemcitabine hydrochloride 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide N-DESMETHYL IMATINIB

  • 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • STI-571
  • IMATINIB BASE(IMA-3)
  • ImatinibMesylate/Gleevec
  • Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec,
  • IMATINIB MESYLATE (IMATINIB METHANESULFONATE)
  • alpha-IMATINIB MESYLATE
  • Imatinib mesylate(TINIBS )
  • Imatinib mesylate
  • Imatinib Methanesulphonate Salt
  • N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)-4-((4-Methylpiperazin-1-yl)Methyl)benzaMide Methanesulfonate
  • N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonic acid
  • ST-1571 Mesylate
  • Imatinib mesylate 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate
  • CGP 57148
  • Genfatinib
  • Imatinib mesylate, >=99%
  • 4-(4-methylpiperazinomethyl)benzoyl chloride dihydrochloride
  • 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benz
  • Bcr-abl Inhibitor IV, Imatinib
  • Imatinib mesylate(alpha Form)
  • Imatinib (STI-571) Mesylate
  • Imatinib Mesylate 220127-57-1
  • IMATINIB MESYLATE (STI571 MESYLATE)
  • Imatinib mesylate - CGP 57148B | STI 571 | Gleevec
  • GLIVEC; CGP-57148B; STI-571
  • 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
  • Imatinib mesylate / 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Gleevec (Imatinib)
  • IMatinib Mesylate(STI-571)
  • Gleevec, Glivec, CGP-57148B, STI-571
  • 4-[(4-Methyl-1-piperazinyl)Methyl]-N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]benzaMide Methanesulfonate
  • GLIVEC
  • GLEEVEC
  • IMATINIB METHANESULFONATE
  • CGP-57148B
  • 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Gleevac
  • Gleevec (IMatinib Mesylate)
  • CGP54148B
  • CGP54148B; STI571; GLEEVEC;GLIVEC
  • 4-(4-Methylpiperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)phenyl]benzaMide Methanesulfonic acid salt
  • Imantinib mesylate
  • N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)-4-(4-Methylpiperazin-1-yl)benzaMide Methanesulfonate
  • tinib Mesylate
  • Imatinib mesylate (Gleevec, Glivec, CGP-57148B, STI-571)
  • Imatinib for system suitability
  • Bcr-abl Inhibitor IV, Imatinib - CAS 220127-57-1 - Calbiochem
  • Imatinib (Glivec)
  • Imatinib for system suitability CRS
  • Imatinib mesilate CRS
  • Imatinib mesylate salt
  • ImatinibMesylate&gt
  • Imatinib Mesylate β form
  • Imatinib mesyL
  • Imatinib mesylate(API)
  • Imatinib mesylate USP/EP/BP